Teva Pharmaceuticals

Teva Pharmaceuticals, headquartered in Israel and operating in the Pharmaceutical Preparation Manufacturing industry, has established a net-zero ambition and near-term reduction targets for its carbon emissions.

For the most recent reported year, 2025, Teva Pharmaceuticals' total Scope 1 emissions were 229,331,000 kg CO2e, and its Scope 2 market-based emissions were 161,989,000 kg CO2e. The company also reported comprehensive Scope 3 emissions, including purchased goods and services at 2,172,650,000 kg CO2e, and use of sold products at 715,334,000 kg CO2e.

Teva Pharmaceuticals has committed to several reduction targets:

• Near-term targets: The company aims to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 25% by 2025 and by 46% by 2030, using 2019 as the base year. Additionally, Teva Pharmaceuticals targets a 25% reduction in absolute Scope 3 GHG emissions by 2030, against a 2020 baseline.
• Long-term target: Teva Pharmaceuticals has stated its intention to achieve net-zero emissions across its operations and value chain by 2045.

These targets are in line with the Science Based Targets initiative (SBTi), with the Scope 1 and 2 targets classified as consistent with keeping warming to 1.5°C.